{"name":"GeNeuro SA","slug":"geneuro-sa","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"GNbAC1","genericName":"GNbAC1","slug":"gnbac1","indication":"Multiple sclerosis","status":"phase_2"}]}],"pipeline":[{"name":"GNbAC1","genericName":"GNbAC1","slug":"gnbac1","phase":"phase_2","mechanism":"GNbAC1 is a recombinant immunoglobulin targeting the human immunoglobulin G1 (IgG1) Fc region.","indications":["Multiple sclerosis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitAJBVV95cUxOSlZvRWx2eTJMMEJTRm1lVWpDZHctMlhOcDRmWnBEQkZsbDNySm9JSnY4R3BQY2NlbUd6QkFfM3RnMGt2TmxfUElKMXJWek5lWnJtdms1RUEzWWhPOWZiTzc5RHJkVUFURDVrN2Z0S0VsOGY3ZFV1U3hBWXluTnhPMzRwbmItWHg5U2Fnd2NXSmUwdERwNGhTR1BEVDlFYWl1TTZVWnJOci1oWF80NGhpUjBBVVBUN0ZBWG1MdjBsTGloYURvakhwN0ZUaGM1N19HUlRrb3hWaFFFN0VjOERYbUhsMy05Qklmb3UyaE94U0FHSjIxbHowZ3lQRUdYZl9zdjJqU1lRNURRQVhpZUpmeWduSEFVSENwY0FyVFFtUkZVSG9OcmRUeUtreDkzaV9uV2hVQg?oc=5","date":"2025-01-14","type":"pipeline","source":"PR Newswire","summary":"Multiple Sclerosis Market in US to Grow by USD 4.99 Billion from 2025-2029, Driven by a Strong Vendor Pipeline and AI-Powered Market Evolution - Technavio - PR Newswire","headline":"Multiple Sclerosis Market in US to Grow by USD 4.99 Billion from 2025-2029, Driven by a Strong Vendor Pipeline and AI-Po","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxNYVZGb1d4SlV6bHhTQ0RSVURidk9lekxZR0JyZlM1OEFCcmNBcnpaNGZCZzdybERwZFNjb2VSSjJmWXJpdUMwbWMxZW93ZXY0SV8wUDRBSVRaaFRxeFpPNXFCZ3JqQUpwbEtWdFNEY2lPYURISVF2QmV4aG8zdmw0dlpxV0RFT3VnV29fRmdkdDd3WkVrM1VJaU5rb0J3aHdGbkhGeE0yRFM4clBOQWxGT0JaTFcxS3VlVHZzNHU1YjlhQlEtcG1OUjlzdEp1QjU5RlNBeXNlcHZJLVl6SVBONkdkTQ?oc=5","date":"2024-11-13","type":"pipeline","source":"PR Newswire","summary":"75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight - PR Newswire","headline":"75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxPbkdobWFuXzdITklNSHFEYVkxdXVRVjc1aWtJRmlSR3lXYzNfekVfWTkyM0ppaTAzZTVSQXRnNnFwOURqLUZzWW13SG1xMlY2QVZ1dk5UamJfYkhaVkVEUXp4YkMwcHpRazBsUTMwV1QwUVZkcVhQak1WRnlKQXRlODBoQk9SclFySGVoTUVZSGdNUmVIQldmZTZ1NjZXR010NmhHYmpqSUZvVU5KdmJ2Zk9TUVhkNzJjWDk2MWNWRklCQ0pS?oc=5","date":"2024-09-10","type":"pipeline","source":"PR Newswire","summary":"BTK Inhibitors Market to Observe Stunning Growth by 2034 | DelveInsight - PR Newswire","headline":"BTK Inhibitors Market to Observe Stunning Growth by 2034 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPVThiWWwtQ2VPZFdCbmZtMlFCM3gwTURxTF9TODczbU53dDRkNnFzN1pyRFBMNXg3dGZRb0Q1QUJzZ3J0UVVaelFCcE9rME95NW9xSWhVMm9zLVF6SEVaTG41VUZWVklqZkFOYko4RGNJSjBHVnI1OXZQYjNPNkRsSWRBRHdaci1RR0VoNWpMWW9XZ0xGbXJZUVpndmNCOU5GMFVWTlVWX091X191NkxkbzRQbzU1ckczZTF4Z0FxUQ?oc=5","date":"2024-06-28","type":"trial","source":"Fierce Biotech","summary":"GeNeuro's long COVID trial fails, triggering layoffs and search for strategic alternatives - Fierce Biotech","headline":"GeNeuro's long COVID trial fails, triggering layoffs and search for strategic alternatives","sentiment":"negative"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}